Combining Antibody-Drug Conjugates and Immunotherapy: mechanistic insights and clinical observations

Combining Antibody-Drug Conjugates and Immunotherapy: mechanistic insights and clinical observations

Monday, March 29, 2021 4:20 PM to 4:40 PM · 20 min. (Africa/Abidjan)
Antibodies
Armed antibodies
Presentation

Information

  • MMAE-based ADCs have demonstrated the potential to change the natural history of multiple cancers
  • MMAE, the cytotoxic payload, has been shown to induce immunogenic cell death
  • Combining MMAE-based ADCs with immunotherapy has the promise of augmenting the benefit of each of these therapies

Nancy Whiting, Executive Vice President, Development, Seattle Genetics 

Log in

See all the content and easy-to-use features by logging in or registering!